A SYSTEMATIC review by the American Society of Hematology (ASH) has found no evidence to support sickle cell trait (SCT) as a cause of acute pain crises or sudden exertion-related death. This finding ...

Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia ... sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia ...

Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

This makes it difficult for those with Sickle Cell Anemia, who are of African descent. “Many of those patients require up to 100 transfusions of blood every single year. It’s a very painful ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes ...